5

10

15

20

25

## **CLAIMS**

## 1. A compound of the formula

**(l)** 

or a pharmaceutically acceptable salt thereof.

- 2. A pharmaceutical composition for treating a disorder or condition selected from Alzheimer's disease, Crutzfield-Jacob's disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, Down's syndrome, pancreatitis, inclusion body myocitis, other peripheral amyloidoses and diabetes in a mammal, including a human, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.
- 3. A method of treating a disorder or condition selected from Alzheimer's disease, Crutzfield-Jacob's disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, Down's syndrome, pancreatitis, inclusion body myocitis, other peripheral amyloidoses and diabetes in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
- 4. A method according to claim 3, wherein the disorder or condition being treated is Alzheimer's disease.
  - 5. A method according to claim 3, wherein the disorder or condition being treated is Down's syndrome.
  - 6. A method according to claim 3, wherein the disorder or condition being treated is amyotrophic lateral sclerosis.
  - 7. A method according to claim 3, wherein the disorder or condition being treated is stroke.
  - 8. A method according to claim 3, wherein the disorder or condition being treated is head trauma.

5

15

20

- 9. A method according to claim 3, wherein the disorder or condition being treated is a diabetes.
- 10. A method according to claim 3, wherein the disorder or condition being treated is pancreatis.
- 11. A method according to claim 3, wherein the disorder or condition being treated is inclusion body myocitis.
- 12. A method according to claim 3, wherein the disorder or condition being treated is a prion disorder.
- 13. A method according to claim 3, wherein the disorder or condition being treated is Crutzfield-Jacob's disease.
  - 14. A method according to claim 3, wherein the disorder or condition being treated is progressive supranuclear palsy.
  - 15. A method according to claim 3, wherein the disorder or condition being treated is selected from vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Crutzfield-Jacob's disease, substance-induced persisting dementia, dementia due to multiple etiologies, and dementia not otherwise specified (NOS), or the disorder or condition is a dementia of the Alzheimer's type and is selected from the group consisting of dementia of the Alzheimer's type with early onset uncomplicated, dementia of the Alzheimer's type with early onset with delusions, dementia of the Alzheimer's type with late onset uncomplicated, dementia of the Alzheimer's type with late onset with delusions and dementia of the Alzheimer's type with late onset mood.